GO:0008556 P-type potassium transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008556 describes P-type ATPase activity that couples ATP hydrolysis to potassium import across a membrane.
• The reaction is ATP + H2O + K+(out) = ADP + phosphate + K+(in), with a phosphorylated enzyme intermediate.
• Na+/K+-ATPase (ATP1A1-4, ATP1B1-3) is the best-characterized member, maintaining the electrochemical gradient essential for cell volume, excitability, and secondary transport.
• Gastric H+/K+-ATPase (ATP4A/ATP4B) is a related P-type pump targeted by proton-pump inhibitors and potassium-competitive acid blockers.
• Dysregulation of these transporters is linked to cancer, cardiac disease, and neurological disorders.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable precise functional dissection of P-type potassium transporters.
Description
P-type potassium transmembrane transporter activity (GO:0008556) is a molecular function that enables ATP-dependent transfer of potassium ions across a membrane against their electrochemical gradient. This activity is essential for maintaining the resting membrane potential, regulating cell volume, and driving secondary active transport in virtually all animal cells. The term encompasses a family of P-type ATPases that form a phosphorylated intermediate during the transport cycle, distinguishing them from other potassium channels and transporters. The most extensively studied member is the Na+/K+-ATPase, which exports three sodium ions and imports two potassium ions per ATP hydrolyzed. Other members include the gastric H+/K+-ATPase, which acidifies the stomach lumen, and the non-gastric H+/K+-ATPase, which contributes to potassium homeostasis in kidney and colon. Understanding GO:0008556 is therefore central to physiology, pharmacology, and disease research.
P-type potassium transmembrane transporter activity At A Glance
| GO ID | GO:0008556 |
|---|---|
| GO term | P-type potassium transmembrane transporter activity |
| Ontology | molecular_function |
| Synonym | K+-importing ATPase activity; potassium-transporting ATPase activity; ATP-dependent potassium transmembrane transporter activity |
| Major function | ATP-dependent potassium import across a membrane, often coupled to sodium or proton export |
| Reaction | ATP + H2O + K+(out) = ADP + phosphate + K+(in) |
| Catalytic mechanism | Formation of a phosphorylated enzyme intermediate (P-type) |
| Representative genes | ATP1A1, ATP1A2, ATP1A3, ATP1A4, ATP1B1, ATP1B2, ATP1B3, ATP4A, ATP4B, ATP12A |
| Subcellular location | Plasma membrane |
What Is GO:0008556?
GO:0008556 defines a molecular function: the transfer of potassium ions from one side of a membrane to the other, driven by ATP hydrolysis, according to the reaction ATP + H2O + K+(out) = ADP + phosphate + K+(in). This activity is characteristic of P-type ATPases that become transiently phosphorylated on a conserved aspartate residue during the catalytic cycle. The term includes synonyms such as K+-importing ATPase activity, potassium-transporting ATPase activity, and ATP-dependent potassium transmembrane transporter activity.
Why Is P-type potassium transmembrane transporter activity Important in Cell Biology?
P-type potassium transmembrane transporter activity is fundamental to animal physiology because it establishes and maintains the sodium and potassium gradients across the plasma membrane. These gradients are required for action potentials, muscle contraction, nutrient uptake, and cell volume regulation. The Na+/K+-ATPase alone consumes a large fraction of cellular ATP, underscoring its energetic and functional importance. Pharmacologically, this activity is the target of cardiac glycosides (e.g., digoxin) and gastric proton-pump inhibitors, making it a validated drug target. In disease, mutations or dysregulation of these transporters cause neurological, cardiac, and renal disorders, and altered expression is observed in multiple cancers.
• Maintains resting membrane potential and excitability in neurons and muscle.
• Drives secondary active transport of nutrients, ions, and neurotransmitters.
• Regulates cell volume and intracellular pH.
• Target of cardiac glycosides used in heart failure and arrhythmia.
• Target of proton-pump inhibitors and potassium-competitive acid blockers for acid-related diseases.
• Mutations in ATP1A2 and ATP1A3 cause familial hemiplegic migraine and rapid-onset dystonia-parkinsonism.
• Altered Na+/K+-ATPase expression and localization contribute to cancer cell migration and metastasis.
• Palmitoylation regulates cardiac sodium pump function and its response to stress.
• Provides a model system for studying P-type ATPase mechanism and ion transport.
• Enables CRISPR-based functional genomics of ion transport in health and disease.
P-type potassium transmembrane transporter activity: mechanism, structure, and regulation
What Happens During P-type potassium transmembrane transporter activity?
In simple terms: The transporter uses energy from ATP to pump potassium into the cell while moving other ions out.
The transport cycle begins with binding of cytoplasmic sodium (or protons) and ATP to the pump, followed by phosphorylation of a conserved aspartate residue and occlusion of the ions. Subsequent conformational changes expose the ions to the extracellular side, where they are released, and potassium binds from the outside. Potassium binding triggers dephosphorylation and a return to the inward-facing conformation, releasing potassium into the cytoplasm. For the Na+/K+-ATPase, the stoichiometry is three sodium ions exported and two potassium ions imported per ATP hydrolyzed.
Ion binding and occlusion
In simple terms: The pump grabs ions tightly so they cannot leak back before being released on the other side.
High-resolution structures of Na+/K+-ATPase reveal distinct binding sites for sodium and potassium within the transmembrane domain. Ion occlusion prevents back-leakage and ensures coupled transport. Potassium binding at the extracellular-facing sites is a key step that triggers dephosphorylation and the E2 to E1 transition.
Conformational transitions
In simple terms: The protein changes shape like a revolving door to move ions across the membrane.
P-type ATPases cycle between at least two major conformations, E1 and E2, which interconvert via phosphorylation and dephosphorylation. These transitions alter the accessibility of ion-binding sites from one side of the membrane to the other. The energy from ATP hydrolysis is used to drive these conformational changes against the ion gradient.
Structure and Composition of P-type potassium transmembrane transporter activity
In simple terms: The pump is built from several protein subunits that work together.
The Na+/K+-ATPase is a heterodimer of a catalytic alpha subunit (approximately 100 kDa) and a heavily glycosylated beta subunit. The alpha subunit contains the ATP-binding site, the phosphorylation site, and the ion-binding residues. The beta subunit is required for proper folding, membrane insertion, and stability of the alpha subunit. In some tissues, a small regulatory subunit called FXYD protein modulates pump activity.
Gastric H+/K+-ATPase composition
In simple terms: The stomach pump has a similar architecture but swaps potassium for protons.
The gastric H+/K+-ATPase consists of an alpha subunit (ATP4A) and a beta subunit (ATP4B). It exports protons into the stomach lumen in exchange for potassium, contributing to gastric acid secretion. This pump is the target of proton-pump inhibitors such as omeprazole and potassium-competitive acid blockers like tegoprazan.
Molecular Mechanism of P-type potassium transmembrane transporter activity
In simple terms: The pump uses ATP as an energy source and changes its own chemistry to move ions.
The catalytic cycle involves ATP binding, autophosphorylation of a conserved aspartate, and subsequent hydrolysis of the phosphoenzyme. Potassium acts as a counterion that stimulates dephosphorylation, completing the cycle. Regulatory factors such as palmitoylation can modify pump activity and trafficking. In cancer cells, the Na+/K+-ATPase can also function as a signaling scaffold independent of ion transport.
Key Genes Involved in GO:0008556 P-type potassium transmembrane transporter activity
The following genes encode subunits or isoforms of P-type potassium transporters and are central to research on GO:0008556.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ATP1A1 | Catalytic alpha-1 subunit of Na+/K+-ATPase; ubiquitous | Essential for ion homeostasis; mutations linked to hypertension and cancer |
| ATP1A2 | Catalytic alpha-2 subunit; expressed in brain, heart, skeletal muscle | Mutations cause familial hemiplegic migraine |
| ATP1A3 | Catalytic alpha-3 subunit; neuronal | Mutations cause rapid-onset dystonia-parkinsonism and alternating hemiplegia |
| ATP1A4 | Catalytic alpha-4 subunit; testis-specific | Role in sperm motility; potential contraceptive target |
| ATP1B1 | Beta-1 subunit; ubiquitous | Required for pump maturation; mutations cause renal tubular dysgenesis |
| ATP1B2 | Beta-2 subunit; neural | Modulates pump in brain; implicated in neurodegeneration |
| ATP1B3 | Beta-3 subunit; widespread | Associated with cancer progression |
| ATP4A | Catalytic alpha subunit of gastric H+/K+-ATPase | Target of proton-pump inhibitors; role in acid secretion |
| ATP4B | Beta subunit of gastric H+/K+-ATPase | Required for pump function; autoimmune target in pernicious anemia |
| ATP12A | Non-gastric H+/K+-ATPase alpha subunit | Contributes to potassium homeostasis in kidney and colon |
| FXYD1 | Regulatory subunit (phospholemman) | Modulates Na+/K+-ATPase in heart; regulated by palmitoylation |
| FXYD2 | Regulatory subunit | Mutations cause hypomagnesemia |
| FXYD3 | Regulatory subunit | Overexpressed in cancers |
| FXYD4 | Regulatory subunit | Regulates sodium transport in kidney |
| FXYD5 | Regulatory subunit | Linked to cell adhesion and cancer |
| FXYD6 | Regulatory subunit | Modulates pump activity in brain |
| FXYD7 | Regulatory subunit | Neuronal-specific regulator |
How Is P-type potassium transmembrane transporter activity Regulated?
P-type potassium transporter activity is regulated at multiple levels. Palmitoylation of the cardiac Na+/K+-ATPase modulates its activity and response to stress. Hormones such as aldosterone and insulin regulate pump trafficking and activity. In cancer, the Na+/K+-ATPase can be redistributed to the plasma membrane and act as a signaling scaffold. Gastric H+/K+-ATPase is regulated by histamine, gastrin, and acetylcholine, and is inhibited by proton-pump inhibitors.
P-type potassium transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ATP1A2 | Familial hemiplegic migraine | Knock-in of patient mutation in cell line; neuronal excitability assays |
| ATP1A3 | Rapid-onset dystonia-parkinsonism | Knockout or point-mutation in iPSC-derived neurons |
| ATP1A1 | Hypertension, cancer | Overexpression and knockout in cancer cell lines; migration assays |
| ATP4A | Gastric acid secretion disorders | Knockout in gastric organoids; acid secretion assays |
| ATP1B1 | Renal tubular dysgenesis | Knock-in of patient mutation in kidney cells; transport assays |
Neurological disorders
Mutations in ATP1A2 and ATP1A3 cause familial hemiplegic migraine and rapid-onset dystonia-parkinsonism, respectively. These mutations impair pump function and lead to neuronal hyperexcitability.
Cardiovascular disease
Cardiac glycosides such as digoxin inhibit Na+/K+-ATPase, increasing intracellular calcium and enhancing cardiac contractility. Palmitoylation of the cardiac pump affects its function and may contribute to heart failure.
Cancer
Altered expression and localization of Na+/K+-ATPase subunits are observed in many cancers, where the pump can promote cell adhesion, migration, and metastasis. The beta-3 subunit (ATP1B3) is associated with cancer progression.
Gastric and renal disorders
The gastric H+/K+-ATPase is the target of proton-pump inhibitors used to treat acid-related diseases. Non-gastric H+/K+-ATPase contributes to potassium homeostasis, and its dysfunction may lead to electrolyte imbalances.
From P-type potassium transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ATP1A1 affect cell viability? | CRISPR knockout in HeLa or HEK293 cells |
| How does a specific ATP1A2 mutation alter pump function? | Point mutation knock-in in SH-SY5Y cells |
| Can we tag the endogenous ATP1A1 for live imaging? | Knock-in of fluorescent tag (e.g., GFP) in cancer cell lines |
| Does overexpression of ATP1B3 promote migration? | Overexpression in MCF-7 or MDA-MB-231 cells |
| What is the role of ATP4A in acid secretion? | Knockout in gastric organoids |
| Can we screen for regulators of Na+/K+-ATPase trafficking? | CRISPR library screening in reporter cell lines |
How to Study the P-type potassium transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ATPase activity assay | ATP hydrolysis rate | Assessing pump function in cell lysates |
| Ion flux assay | Potassium or sodium transport | Measuring pump activity in live cells |
| Cryo-EM | Three-dimensional structure | Determining ion-binding sites and conformations |
| Live-cell imaging | Subcellular localization | Tracking pump trafficking and recycling |
| CRISPR knockout | Loss-of-function phenotype | Identifying essential roles in cell lines |
| CRISPR point mutation | Effect of specific variants | Modeling disease mutations |
| Overexpression | Gain-of-function effects | Studying cancer cell migration |
| Proteomics | Protein interactions | Identifying pump-associated proteins |
CRISPR knockout and point mutation
CRISPR-Cas9 can generate knockout cell lines to study loss of function of P-type potassium transporters. Point mutations can be introduced to model disease-associated variants and assess their impact on pump activity.
Knock-in and overexpression
Knock-in of tags or reporters allows visualization and quantification of endogenous pumps. Overexpression studies help determine gain-of-function effects and interactions.
Biochemical and transport assays
ATPase activity assays measure phosphate release or ATP consumption. Ion flux can be monitored using fluorescent indicators or electrophysiology.
Structural and imaging approaches
Cryo-EM and X-ray crystallography provide structural insights into ion binding and conformational changes. Live-cell imaging of tagged pumps reveals trafficking and localization.
How CRISPR Can Be Used to Study GO:0008556 P-type potassium transmembrane transporter activity
Knockout
CRISPR knockout of ATP1A1 or other P-type potassium transporter genes can reveal their essential roles in ion homeostasis and cell survival. However, complete knockout of ubiquitous isoforms may be lethal, requiring inducible systems.
Point Mutation
Point mutations identified in patients (e.g., ATP1A2 or ATP1A3) can be introduced into cell lines to study their effects on pump function and neuronal excitability.
Knock-in
Knock-in of fluorescent tags or epitope tags allows real-time tracking of endogenous pumps and their regulation by palmitoylation or other modifications.
Overexpression
Overexpression of specific subunits (e.g., ATP1B3) can mimic cancer-associated upregulation and help identify downstream signaling pathways.
How EDITGENE Supports P-type potassium transmembrane transporter activity Research
Researchers studying P-type potassium transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in ion transport, disease, or drug response. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this discovery.
Contact EDITGENE today to design your custom CRISPR model for P-type potassium transmembrane transporter activity research.
Frequently Asked Questions About P-type potassium transmembrane transporter activity
What is GO:0008556?
GO:0008556 is the Gene Ontology term for P-type potassium transmembrane transporter activity, an ATP-dependent molecular function that moves potassium ions across a membrane.
What genes are involved in P-type potassium transmembrane transporter activity?
Key genes include ATP1A1-4, ATP1B1-3, ATP4A, ATP4B, ATP12A, and FXYD family members.
What is the reaction catalyzed by P-type potassium transporters?
The reaction is ATP + H2O + K+(out) = ADP + phosphate + K+(in).
How does the Na+/K+-ATPase work?
It exports three sodium ions and imports two potassium ions per ATP hydrolyzed, maintaining electrochemical gradients.
What diseases are linked to P-type potassium transporters?
Mutations cause neurological disorders like familial hemiplegic migraine and rapid-onset dystonia-parkinsonism, and altered expression is seen in cancer and heart disease.
What is the role of ATP4A and ATP4B?
They form the gastric H+/K+-ATPase, which secretes acid into the stomach and is targeted by proton-pump inhibitors.
How can I study P-type potassium transporter function?
Use CRISPR knockout, point mutation, knock-in, overexpression, ATPase assays, ion flux measurements, and structural methods.
What are FXYD proteins?
FXYD proteins are small regulatory subunits that modulate Na+/K+-ATPase activity in a tissue-specific manner.
Is the Na+/K+-ATPase a drug target?
Yes, cardiac glycosides like digoxin inhibit it to increase cardiac contractility.
What CRISPR models are available for P-type potassium transporters?
EDITGENE offers knockout, point mutation, knock-in, overexpression, and library screening services for these genes.
Conclusion
P-type potassium transmembrane transporter activity (GO:0008556) is a fundamental molecular function that maintains ion gradients essential for life. Its best-characterized members, the Na+/K+-ATPase and gastric H+/K+-ATPase, are validated drug targets and are implicated in neurological, cardiovascular, and neoplastic diseases. Continued research using CRISPR-based models will further elucidate their roles and uncover new therapeutic opportunities.
References
- 1. Kaplan JH. 2002. Biochemistry of Na,K-ATPase.. Annu Rev Biochem 71:511-35 PMID: 12045105
- 3. Lingrel JB et al.. 1990. Molecular genetics of Na,K-ATPase.. Prog Nucleic Acid Res Mol Biol 38:37-89 PMID: 2158121
- 4. Howie J et al.. 2018. Greasing the wheels or a spanner in the works? Regulation of the cardiac sodium pump by palmitoylation.. Crit Rev Biochem Mol Biol 53(2):175-191 PMID: 29424237
- 5. Silva CID et al.. 2021. Na/K-ATPase: Their role in cell adhesion and migration in cancer.. Biochimie 185:1-8 PMID: 33713729
- 6. Jorgensen PL et al.. 2003. Structure and mechanism of Na,K-ATPase: functional sites and their interactions.. Annu Rev Physiol 65:817-49 PMID: 12524462
- 7. Cerf NT et al.. 2024. How ligands modulate the gastric H,K-ATPase activity and its inhibition by tegoprazan.. J Biol Chem 300(12):107986 PMID: 39547508
- 8. Apell HJ. 2004. How do P-type ATPases transport ions?. Bioelectrochemistry 63(1-2):149-56 PMID: 15110265
